Analysis of factors for Bio-free remission due to the Tight control by Remicade in rheumatoid arthritis patients. Birdie study

Analysis of factors for Bio-free remission due to the Tight control by Remicade in rheumatoid arthritis patients. Birdie study - Burdie study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009435

Enrollment

100

Registered

2012-11-29

Start date

2012-09-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with rheumatoid arthritis 2. Patients who have been treated with infliximab 3. Patients who have achieved SDAI remission for over 24 weeks

Exclusion criteria

Exclusion criteria: Patients who already achieved remission after stopping infliximab

Design outcomes

Primary

Measure	Time frame
Identification of risk factors for relapse during the observation period until 2021.3.31 after IFX withdrawal	—

Countries

Japan

Contacts

Public ContactTatsuya Koike

Osaka City University Medical School Center for Senile degenerative Disorders (CSDD)

tatsuya@med.osaka-cu.ac.jp06-6645-3984

Outcome results